Inja Waldhauer
Hoffmann-La Roche
43 Papers
125 Citations
Inja Waldhauer is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Medicine & IL-2 receptor. The author has an hindex of 12, co-authored 35 publications.
Chat about Author
Papers
Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose
Claudia Ferrara,Sandra Grau,Christiane Jäger,Peter Sondermann,Peter Brünker,Inja Waldhauer,Michael Hennig,Armin Ruf,Arne C. Rufer,Martine Stihle,Pablo Umana,Jörg Benz +11 more
TL;DR: A detailed, molecular understanding of the regulatory role of Fc-oligosaccharide core fucosylation in improving ADCC is obtained and a unique mechanism by which the immune system can regulate antibody-mediated effector functions is suggested.
756
Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
Sylvia Herter,Frank Herting,Olaf Mundigl,Inja Waldhauer,Tina Weinzierl,Tanja Fauti,Gunter Muth,Doris Ziegler-Landesberger,Erwin van Puijenbroek,Sabine Lang,Minh Ngoc Duong,Lina Reslan,Christian Gerdes,Thomas Friess,Ute Baer,Helmut Burtscher,K. Michael Weidner,Charles Dumontet,Pablo Umana,Gerhard Niederfellner,Marina Bacac,Christian Klein +21 more
TL;DR: The first preclinical in vitro and in vivo comparison of GA101 (obinutuzumab), a novel glycoengineered type II CD20 monoclonal antibody, with rituximab and ofatumumab, the two currently approved type I CD20 antibodies was reported in this article.
338
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.
Christian Klein,Inja Waldhauer,Nicolini Valeria G,Anne Freimoser-Grundschober,Tapan K. Nayak,Danielle J. Vugts,Claire Dunn,Marije Bolijn,Jörg Benz,Martine Stihle,Sabine Lang,Michaele Roemmele,Hofer Thomas U,Erwin van Puijenbroek,David Wittig,Samuel Moser,Oliver Ast,Peter Brünker,Ingo H. Gorr,Sebastian Neumann,Maria Cristina De Vera Mudry,Heather Hinton,Flavio Crameri,Jose Saro,Stefan Evers,Christian Gerdes,Marina Bacac,Guus A.M.S. van Dongen,Ekkehard Moessner,Pablo Umana +29 more
TL;DR: Preclinical data support the ongoing clinical investigation of the cergutuzumab amunaleukin immunocytokine with abolished CD25 binding for the treatment of CEA-positive solid tumors in combination with PD-L1 checkpoint blockade and ADCC competent antibodies.
245
A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.
Laurence B. Peterson,Charles J.M. Bell,Sarah Howlett,Marcin L. Pekalski,Kevin Brady,Heather Hinton,Denise Sauter,John A. Todd,Pablo Umana,Oliver Ast,Inja Waldhauer,Anne Freimoser-Grundschober,Ekkehard Moessner,Christian Klein,Ralf Hosse,Linda S. Wicker,Linda S. Wicker +16 more
TL;DR: A next-generation immunotherapy using a long-lived and Treg-selective IL-2 that activates and expands functional Tregsin vivo is described to the extent that their autoimmune disease condition dictates opening up the possibility for remissions and cures.
135
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells
L. Codarri Deak,V González Nicolini,Masao Hashimoto,Maria Karagianni,Petra C. Schwalie,Laura Lauener,Eleni Maria Varypataki,Marine Richard,Esther Bommer,Johannes Sam,Stefanie Joller,Mario Perro,Floriana Cremasco,Leo Kunz,Emilio Yanguez,Tamara Hüsser,Ramona Schlenker,Marisa Mariani,Vinko Tosevski,Sylvia Herter,Marina Bacac,Inja Waldhauer,Sara Colombetti,Xavier Gueripel,Stephan Wullschleger,Mélanie Tichet,Douglas Hanahan,Haydn T. Kissick,Stéphane Leclair,Anne Freimoser-Grundschober,Stefan Seeber,Volker Teichgräber,Rafi Ahmed,Christian Klein,Pablo Umana +34 more
TL;DR: In this article , a new immunocytokine, PD1-IL2v, was introduced, which overcomes the need for CD25 binding by docking in cis to PD-1.